Epitalon
Synthetic Pineal Tetrapeptide | Telomerase Activator & Anti-Aging
Epitalon (Epithalon, AEDG) is a synthetic tetrapeptide consisting of four amino acids (Ala-Glu-Asp-Gly) based on a naturally occurring pineal gland peptide. Developed by Russian scientist Vladimir Khavinson and studied for over 35 years, Epitalon is primarily researched for its ability to activate telomerase, extend telomeres, and potentially slow cellular aging through multiple mechanisms including melatonin regulation and gene expression modulation. IMPORTANT: Current Western dosing protocols may be 50-100x higher than necessary due to translation errors from Russian literature.
Daily dose
100-500μg
Frequency
1x daily
Cycle length
10-20 days
Storage
2-8°C
Key benefits
Telomerase activation for telomere extension, enhanced melatonin production, improved immune function, potential lifespan extension, and systemic anti-aging effects. IMPORTANT: Current protocols may use 50-100x higher doses than needed based on Russian research.
How it works
Activates telomerase enzyme at extremely low concentrations (10⁻¹⁷ to 10⁻¹⁵ M) to maintain telomere length, stimulates pineal gland for melatonin production, modulates gene expression through epigenetic mechanisms.
Dosage protocols
Goal
Evidence-Based Protocol (Recommended)
Dose
200-500μg · Daily
Route
Subcutaneous
Goal
Conservative Start
Dose
100μg · Daily
Route
Subcutaneous
Goal
Russian Clinical Equivalent
Dose
300μg · Daily
Route
Subcutaneous
Goal
Traditional Western (Likely Overdose)
Dose
5-10mg · Daily
Route
Subcutaneous
Goal
Ultra-Low Dose
Dose
50μg · Daily
Route
Subcutaneous
Research indications
anti Aging
neuroprotection
immunity
Administration
Interactions
Safety notes
Generally well-tolerated with minimal side effects in studies
Corrected microgram dosing reduces unnecessary peptide exposure
Theoretical concern about telomerase in cancer patients - avoid if active malignancy
May cause mild injection site reactions
Some users report vivid dreams due to melatonin enhancement
No severe adverse events reported in 30+ years of Russian clinical use
Current Western protocols likely represent significant overdosing based on translation errors
Research studies
Neurogenesis Gene Expression Study (2020)
Human stem cells | 0.01μg/ml | 7 days | Enhanced differentiation
Epitalon upregulated neurogenic differentiation markers (Nestin, GAP43, β-Tubulin III) by 1.6-1.8 fold in human gingival mesenchymal stem cells at extremely low concentrations, suggesting epigenetic regulation of neurogenesis.
View study →Retinal Degeneration Trial (2019)
Human (AMD patients) | 5μg per eye | 10 days | 90% positive response
Patients with age-related macular degeneration showed improved visual acuity and slowed disease progression using only 5 micrograms per eye daily, suggesting neuroprotective effects at very low doses.
View study →Telomerase Activation in Human Fibroblasts (2003)
Human cells | 0.1μM | 5 days | Extended Hayflick limit
Landmark study showed Epitalon activated telomerase in telomerase-negative human fibroblasts, extending their replicative lifespan from 34 to 44+ passages while maintaining telomere length comparable to young cells.
View study →Lifespan Extension in Mice (2003)
Mice | 1μg per mouse | 5 days/month | 25% lifespan increase
Aging mice treated with extremely low doses of Epitalon (approximately 30-40 μg/kg) showed significant lifespan extension and reduced chromosomal aberrations, demonstrating efficacy at microgram doses.
View study →Pineal Function with Low-Dose Epitalon (2001)
Human (elderly) | 10μg daily | 10 days | Normalized melatonin
Elderly patients showed restoration of circadian melatonin rhythm, improved sleep quality, enhanced emotional stability, and increased physical stamina after low-dose synthetic Epitalon treatment. This study used microgram, not milligram doses.
View study →Russian Clinical Trials with Epithalamin Extract (1992-2007)
Human | Epithalamin 10mg IM | 15 years follow-up | Reduced mortality
IMPORTANT NOTE: This study used epithalamin (natural extract), not synthetic epitalon. Long-term clinical observations by Khavinson team showed significantly lower all-cause mortality in elderly subjects receiving periodic epithalamin courses compared to controls, with improved cardiovascular and immune parameters.
View study →